AVCN583601 (3% Cannabidiol cream) ( DrugBank: Cannabidiol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 36 | Epidermolysis bullosa | 1 |
36. Epidermolysis bullosa
Clinical trials : 160 / Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04613102 (ClinicalTrials.gov) | August 1, 2020 | 27/10/2020 | The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | Epidermolysis Bullosa;Pain;Itch | Drug: AVCN583601 (3% Cannabidiol cream) | Elena Pope | Avicanna Inc | Withdrawn | 4 Years | 50 Years | All | 0 | Phase 2/Phase 3 | Canada |